Work

Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody

Year: 2026
Type: article
Abstract: Etentamig is an investigational B-cell maturation antigen (BCMA) x CD3 bispecific T-cell engager, composed of a low-affinity CD3 binding domain, potentially reducing cytokine release syndrome (CRS) and infections, a high-avidity bivalent BCMA-binding domain, and retained FcRn binding supporting monthly (Q4W) dosing after a single step-up dose (SUD). We report long-term efficacy and safety from the ongoing, open-label, phase 1 (dose escalation/expansion; NCT03933735) and Arm A of the phase 1b (NCT05650632) studies of etentamig in adult patients with relapsed/refractory multiple myeloma, triple-class exposure, and ≥3 prior lines of therapy (LoT). In phase 1, patients received etentamig 60 mg Q4W or 40 mg Q3W, and in phase 1b, a SUD on Day 1 and 60 mg Q4W on Day 4. Among 146 patients (median age: 68 years; median [range] prior LoT: 4 [3-23]), median follow-up was 13 months (range: 1-48). Objective responses and ≥ very good partial responses occurred in 66% and 54% of patients. Median duration of response and progression-free survival were not reached. Pooled data suggest etentamig has a manageable safety profile, with Grade 3/4 neutropenia and infection occurring in 38% and 23% of patients. In phase 1b Arm A (n=23), overall CRS incidence was 30% (26% Grade 1; 4% Grade 2) with modified dexamethasone premedication and 1 SUD; median onset was 22.3 hours (range: 5.5-29.6) hours, with resolution in 20.7 hours (range: 1.8-131.7). Etentamig's molecular design may be associated with the observed clinical efficacy and tolerability while also potentially supporting extended dosing intervals.
Source: Blood
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,500
OpenAlex ID: W7233893068
FWCI:
Cites:
Cited by:
Related to: 10